Biotech Values

[DewDiligence]

Agreed that 85% SVR with excellent tolerability will trump 90%+ SVR with so-so tolerability. However, let’s bear in mind that, when measured on an ITT basis, the SVR metric subsumes tolerability insofar as dropouts never count as SVR’s.

I’m less convinced than you are that “convenience” — i.e. qD vs BID dosing — makes a lot of difference in 12w course of therapy.